
Sign up to save your podcasts
Or


Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.
By Dr. Neil Love4.4
3030 ratings
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.

322 Listeners

40 Listeners

66 Listeners

75 Listeners

15 Listeners

17 Listeners

13 Listeners

0 Listeners

6 Listeners

119 Listeners

59 Listeners

125 Listeners

43 Listeners

27 Listeners

60 Listeners

86 Listeners

189 Listeners